 BOSTON, MA ACCESSWIRE January 19, 2021 Pieris Pharmaceuticals, Inc. NASDAQ:PIRS , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin technology platform for respiratory diseases, cancer, and other indications, today announced that the U.S. Food and Drug Administration FDA has lifted the previously announced partial clinical hold on the phase 1 studies of PRS-343. As previously guided, the Company intends to move into a proof-of-concept study of PRS-343 in gastroesophageal cancer. 